

6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 018733/0996

Applicant: Shui-on LEUNG *et al.*

**Title: IMMUNOCONJUGATES AND HUMANIZED ANTIBODIES
SPECIFIC FOR B-CELL LYMPHOMA AND LEUKEMIA CELS**

Appl. No.: 09/741,843

Filing Date: December 22, 2000

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56**

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents know to Applicants in order to comply with Applicants' duty to disclosure pursuant to 37 C.F.R. § 1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

CONCISE EXPLANATION OF
RELEVANCE OF EACH DOCUMENT

Applicants are submitting herewith on Form PTO-1449, a listing of the documents cited by or submitted to the Patent Office in parent application Serial No. 09/127,902, filed August 3, 1998. The relevance of these documents is explained in the parent application.


As provided in 37 C.F.R. § 1.98(d), copies of the documents are not being provided since they were previously cited by or submitted to the Patent Office in parent application Serial No. 09/127,902, filed August 3, 1998.

Since this Information Disclosure Statement is being filed in compliance with 37 C.F.R. § 1.97(b) prior to the mailing date of the first official action, no fee is required in connection with its filing.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialized copy of Form PTO-1449 be returned in accordance with M.P.E.P. § 609.

Respectfully submitted,

April 26, 2001
Date


Bernhard D. Saxe
Reg. No. 28,665

FOLEY & LARDNER
Suite 500
3000 K Street, N.W.
Washington, D.C. 20007-5109
(202) 672-5300

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
018733/0996SERIAL NO.
09/741,843

INFORMATION DISCLOSURE CITATION

APPLICANT

Shui-on LEUNG et al.

FILING DATE

December 22, 2000

GROUP ART UNIT

not yet assigned

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,057,313	10/1991	Shih et al.			
	A2	5,789,554	08/1998	Leung et al.			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	A3	0 239 400	09/30/1987	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A4	Baum et al., Cancer 73(Supl. 3):896-899 (February 1, 1994)
	A5	Belise et al., Proc. of the Am. Assn. for Can. Res., 34:481, #2873 (March 1993)
	A6	Goldenberg, J. Clin. Oncology 9(4):548-564 (April 1991)
	A7	Goldenberg, Scientific Am. Sci. & Med., pp. 64-73 (March/April 1994)
	A8	Gussow and Seeman, Meth. in Enzymology 203:99-121 (1991)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conference with MPEP 609; Draw line through citation if not in conference and not considered. Include any copy of this form with next communication to applicant.

